Lexeo Therapeutics has secured Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for LX2020, its investigational AAV-based gene therapy for PKP2 arrhythmogenic cardiomyopathy. The company said LX2020 now holds RMAT, Orphan Drug and Fast Track designations, strengthening its regulatory position as development continues. RMAT designation is intended to support the development and review of regenerative medicine therapies for serious conditions where early clinical evidence suggests potential to meet unmet medical needs. It also offers enhanced interaction with the FDA, including guidance on clinical development, manufacturing and regulatory pathways. Alongside Orphan Drug and Fast Track status, RMAT designation may provide eligibility for accelerated approval, priority review and rolling review.